Pre-market Feb 14, 2026: 0QF.F Moderna, Inc. (XETRA) posts Q4 beat vs FDA setback: what to watch next

Pre-market on 14 Feb 2026, 0QF.F stock trades at €37.13, up 14.74%, after Moderna reported a fourth-quarter revenue beat and a narrower GAAP loss. The print showed Q4 revenue €678.00 million and GAAP EPS of -€2.11, while management reaffirmed a 10.00% revenue growth target for 2026. The market is parsing the beat against an FDA refusal to review Moderna’s mRNA flu shot. We use 0QF.F stock as our earnings spotlight to link results, valuation, and near-term catalysts for XETRA traders and Europe-based investors.

Earnings snapshot for 0QF.F stock

Moderna reported Q4 revenue €678.00 million and a GAAP net loss of €0.80 billion, or -€2.11 per share. The company cited stronger-than-expected COVID-19 vaccine sales in the U.S. This quarter beat consensus and narrowed the full-year GAAP loss to €2.80 billion on €1.90 billion revenue for 2025.

Market reaction and trading flow for 0QF.F stock

In pre-market XETRA trading the share price jumped from an open of €33.01 to €37.13, a €4.77 rise on 41,498 volume versus an average 1,851 shares. The steep volume spike shows headline-driven repositioning. Price sits above the 50-day average €31.18 and 200-day average €25.17, indicating short-term strength.

Financials and valuation context for 0QF.F stock

Key metrics: EPS -€6.78, reported PE -4.87, market cap €12,896,163,656, year high €46.96 and year low €19.26. Cash per share is €11.55 and current ratio is 3.93, supporting near-term liquidity. Price-to-sales sits near 7.75, and R&D remains large at 156.64% of revenue on a TTM basis.

Technicals and sector backdrop for 0QF.F stock

Momentum indicators show neutral bias: RSI 54.38, MACD histogram -0.78. Bollinger middle band is €37.49 with upper €43.83 and lower €31.15. Healthcare peers traded mixed in Europe today, keeping biotech volatility higher than the broader market. Watch €31.15 support and the €43.83 resistance band during intraday moves.

Meyka AI grade and model forecast for 0QF.F stock

Meyka AI rates 0QF.F with a score of 64.90 out of 100 (Grade: B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly target €32.95 and a quarterly target €47.85. Versus the current €37.13, the quarterly projection implies +28.87% upside, while the monthly projection implies -11.26% near-term downside. Forecasts are model-based projections and not guarantees. See the full company overview on the Meyka stock page.

Risks, catalysts and what to watch next for 0QF.F stock

Primary near-term risk is regulatory: the FDA refused to review the mRNA flu shot application. Product approvals and commercial rollout for respiratory vaccines are key catalysts. Monitor quarterly guidance, U.S. COVID-19 vaccination orders, and partnership updates with AstraZeneca and Merck. Watch liquidity metrics and days sales outstanding at 229.09 days for collection risk.

Final Thoughts

Q4 results gave 0QF.F stock a clear near-term lift in pre-market XETRA trade, driven by a revenue beat and a narrower GAAP loss. The price reaction to €37.13 reflects relief on sales but lingering regulatory risk after the FDA’s refusal to review the mRNA flu shot. Financials show solid cash per share €11.55 and a healthy current ratio 3.93, yet negative EPS and elevated price-to-sales signal valuation caution. Meyka AI’s model offers a split view: a quarterly target €47.85 (implied +28.87%) and a monthly target €32.95 (implied -11.26%). For XETRA traders in Germany, this is an earnings-driven trade setup where momentum and news flow should guide position sizing. We note the stock’s high intraday volume and above-average 50-day price, which support a tactical trade for experienced investors, while longer-term holders should watch regulatory milestones and revenue execution. For more background and the latest headlines see coverage from MarketWatch and deeper note at StockAnalysis. Meyka AI is an AI-powered market analysis platform delivering real-time context for earnings-driven trades.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.